Last reviewed · How we verify
CBDV Compound
CBDV (cannabidivarin) is a non-intoxicating cannabinoid that modulates endocannabinoid signaling and may reduce neuronal hyperexcitability.
CBDV (cannabidivarin) is a non-intoxicating cannabinoid that modulates endocannabinoid signaling and may reduce neuronal hyperexcitability. Used for Epilepsy (phase 2 investigation), Autism spectrum disorder (exploratory).
At a glance
| Generic name | CBDV Compound |
|---|---|
| Sponsor | Montefiore Medical Center |
| Drug class | Cannabinoid |
| Target | CB1, CB2, TRPV1, TRPA1 (putative) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
CBDV is a phytocannabinoid structurally similar to CBD that interacts with cannabinoid receptors and other ion channels in the central nervous system. It is being investigated for its potential anticonvulsant and neuroprotective properties, particularly in conditions characterized by abnormal neuronal activity. The exact molecular mechanisms remain under investigation but may involve modulation of TRPV1, TRPA1, and other ion channels.
Approved indications
- Epilepsy (phase 2 investigation)
- Autism spectrum disorder (exploratory)
Common side effects
- Somnolence
- Diarrhea
- Fatigue
- Decreased appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |